Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2019, there were 578,600 incident cases of esophageal cancer worldwide, and expects that number to increase to 618,900 incident cases by 2028.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck & Co’s Keytruda, Pinnacle Biologics’ Photofrin, and Bristol Myers Squibb’s Opdivo are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The majority of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, while two drugs are being tested in an oral formulation.
- High-impact upcoming events in the esophageal cancer space comprise topline Phase III CheckMate 577 and Phase III CheckMate 648 trial results for Opdivo.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.7%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 91 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for esophageal cancer, followed by Roche
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Endoscopic therapy
10 Chemotherapy
10 Targeted therapy
10 Immunotherapy
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Opdivo for Esophageal Cancer (September 30, 2019)
24 Keytruda for Esophageal Cancer (January 14, 2019)
26 Opdivo for Esophageal Cancer (January 9, 2019)
28 Keytruda for Esophageal Cancer (November 14, 2018)
30 KEY UPCOMING EVENTS
31 KEY REGULATORY EVENTS
31 EU & US At Odds Over Merck’s Keytruda
31 Keytruda Adds Esophageal Cancer Indication
32 PROBABILITY OF SUCCESS
33 LICENSING AND ASSET ACQUISITION DEALS
33 BeiGene Picks Up Asia Rights To Leap’s Lead DKK1 Antibody
33 Deals Shaping The Medical Industry, October 2019
34 REVENUE OPPORTUNITY
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
38 Recent events
39 BIBLIOGRAPHY
39 Prescription information
40 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of esophageal cancer, 2019–28
14 Figure 2: Incident cases of esophageal cancer, by gender, 2019
17 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
18 Figure 4: Pipeline drugs for esophageal cancer, by company
18 Figure 5: Pipeline drugs for esophageal cancer, by drug type
18 Figure 6: Pipeline drugs for esophageal cancer, by classification
24 Figure 7: Opdivo for Esophageal Cancer (September 30, 2019): Phase III – ATTRACTION-3
26 Figure 8: Keytruda for Esophageal Cancer (January 14, 2019): Phase III – KEYNOTE-181
28 Figure 9: Opdivo for Esophageal Cancer (January 9, 2019): Phase III – ATTRACTION-3
29 Figure 10: Keytruda for Esophageal Cancer (November 14, 2018): Phase III – KEYNOTE-181
30 Figure 11: Key upcoming events in esophageal cancer
32 Figure 12: Probability of success in the esophageal cancer pipeline
35 Figure 13: Clinical trials in esophageal cancer
35 Figure 14: Top 10 drugs for clinical trials in esophageal cancer
36 Figure 15: Top 10 companies for clinical trials in esophageal cancer
36 Figure 16: Trial locations in esophageal cancer
37 Figure 17: Esophageal cancer trials status
38 Figure 18: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of esophageal cancer, 2019–28
16 Table 2: Marketed drugs for esophageal cancer
20 Table 3: Pipeline drugs for esophageal cancer in the US
23 Table 4: Opdivo for Esophageal Cancer (September 30, 2019)
25 Table 5: Keytruda for Esophageal Cancer (January 14, 2019)
27 Table 6: Opdivo for Esophageal Cancer (January 9, 2019)
28 Table 7: Keytruda for Esophageal Cancer (November 14, 2018)
34 Table 8: Historical global sales, by drug ($m), 2015–19
34 Table 9: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Venous Thromboembolism (VTE) 
Sign up to the